Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520726 | 0.79 | L3MBTL1 (0.43) | HPGDSMN1; SMN2POLBCYP1A2CYP3A4 | |
| SCHEMBL4119504 | 0.71 | RAB9A (0.63) | SMN1; SMN2POLBALDH1A1MAPTLMNA | |
| SCHEMBL10717004 | 0.70 | SMN1; SMN2 (0.53) | USP2HPGDSMN1; SMN2PKMPOLB | |
| SCHEMBL5359042 | 0.69 | HPGD (0.40) | USP2HPGDSMN1; SMN2PKMALDH1A1 | |
| SCHEMBL8810278 | 0.69 | POLB (0.49) | HPGDSMN1; SMN2POLBCYP1A2ALDH1A1 | |
| SCHEMBL20037056 | 0.69 | GAA (0.60) | SMN1; SMN2ALDH1A1L3MBTL1MAPTKDM4E | |
| SCHEMBL4505557 | 0.69 | HSD17B10 (0.56) | HPGDPOLBALDH1A1MAPTKDM4E | |
| SCHEMBL348699 | 0.68 | SMN1; SMN2 (0.50) | USP2HPGDSMN1; SMN2PKMPOLB | |
| SCHEMBL30038165 | 0.67 | PKM (0.48) | USP2HPGDSMN1; SMN2PKMPOLB | |
| SCHEMBL14435485 | 0.67 | SMN1; SMN2 (0.45) | USP2HPGDSMN1; SMN2PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576203-B2 | Method for producing cyclic diamine derivative | KOWA CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20080045714-A1 | Method for Producing Cyclic Diamine Derivative | KOWA CO., LTD (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1767527-A1 | METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE | Kowa Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045714-A1 | Method for Producing Cyclic Diamine Derivative | SAT1, ACAT2, NAT1 | USP2 2982/4885HPGD 1915/4885SMN1; SMN2 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.